Test Price
2,800 AED✅ Home Collection Available
DPM1 Gene Glycosylation Disorder Type 1E Genetic Test in UAE | 2800 AED | DHA Licensed
Executive Summary & Core Metrics
- Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Processing (Cert: INT/EGQ/2509DA/3139).
- Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily from 8 AM to 11 PM.
- Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by DHA-licensed specialists.
- Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
Congenital Disorder of Glycosylation Type 1E (CDG-1E) is caused by pathogenic variants in the DPM1 gene, disrupting protein glycosylation and leading to severe neurological impairments. This NGS-based genetic test sequences the entire coding region of DPM1 to identify mutations with 99.9% diagnostic accuracy, supporting early diagnosis and tailored management in compliance with DHA regulatory standards.
| Feature | Our Test | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | 99.9% sensitivity with full gene coverage | Limited to targeted single‑exon analysis |
| Method | Next‑Generation Sequencing (NGS) | Sanger Sequencing |
| Turnaround Time | 3–4 Weeks with expedited reporting | 6–8 Weeks |
Physician Insight & Safety Protocols
“Congenital disorders of glycosylation represent a diagnostic challenge that demands precise molecular confirmation. A pathogenic variant in the DPM1 gene provides a definitive diagnosis of CDG type 1E, guiding prognostic counselling and multidisciplinary management. However, genetic results must always be interpreted within the full clinical context and family pedigree.”
— Lina Osama Zaki Quteineh, Consultant Medical Genetics (DHA: 9294403)
Clinical Advisory
Do not discontinue prescribed medication without consulting your doctor. Always maintain current treatment regimens until explicitly advised by your healthcare provider.
Exclusion Criteria & Safety Red Flags
- Minors without legal guardian consent and a formal genetic counselling session (UAE Child Rights Law).
- Individuals unable to provide a detailed three‑generation pedigree and clinical history.
- Emergency Red Flags: New‑onset seizures, acute encephalopathy, or rapid neurological regression—seek immediate medical attention before genetic testing.
Patient FAQ & Clinical Guidance
1. What is the DPM1 gene and how does it relate to glycosylation disorders?
The DPM1 gene encodes a critical enzyme for building the core glycan structure that modifies proteins; pathogenic variants cause Congenital Disorder of Glycosylation Type 1E, manifesting with severe developmental and neurological symptoms.
2. What types of samples are accepted and how is home collection arranged?
We accept whole blood (venous), extracted DNA, or a single dried blood spot on an FTA card collected by our DHA‑licensed mobile phlebotomist under strict cold‑chain protocol. Home collection is available daily from 8 AM to 11 PM.
3. How should I prepare for the test and what pre‑information is required?
A mandatory genetic counselling session is required to draw a family pedigree and document three‑generation medical history before sample collection; no fasting is needed unless specified by your physician.
UAE Regulatory & Data Privacy Adherence
Data Protection & Compliance Framework
All genetic data is processed in strict accordance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Clinical safety and patient consent protocols adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic information is encrypted, access-controlled, and never shared without explicit written consent.
Clinical & Logistical Metadata
| Test Name | DPM1 Gene (CDG-1E) Sequencing |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 Weeks |
| Sample Type / Matrix | Whole Blood (venous), Extracted DNA, or Dried Blood Spot (FTA Card) |
| Methodology Used | Next-Generation Sequencing (NGS) – Full Coding Region Coverage |
| ICD-10-CM Code | E74.8 |
| LOINC Code | 21636-6 |
| DHA Facility License & Laboratory Address | License No. 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians